GSA Capital Partners’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $427K | Sell |
13,574
-11,640
| -46% | -$344K | 0.03% | 1104 |
|
|
2026
Q1 | $624K | Buy |
25,214
+13,124
| +109% | +$313K | 0.04% | 778 |
|
|
2025
Q4 | $282K | Buy |
+12,090
| New | +$269K | 0.02% | 1203 |
|
|
2025
Q3 | – | Sell |
-27,656
| Closed | -$600K | – | 1714 |
|
|
2025
Q2 | $600K | Buy |
27,656
+5,072
| +22% | +$120K | 0.04% | 790 |
|
|
2025
Q1 | $548K | Sell |
22,584
-40,303
| -64% | -$908K | 0.05% | 741 |
|
|
2024
Q4 | $1.31M | Buy |
62,887
+31,450
| +100% | +$676K | 0.1% | 244 |
|
|
2024
Q3 | $625K | Buy |
+31,437
| New | +$583K | 0.05% | 771 |
|
|
2024
Q2 | – | Sell |
-59,838
| Closed | -$954K | – | 1680 |
|
|
2024
Q1 | $954K | Buy |
+59,838
| New | +$902K | 0.08% | 470 |
|
|
2022
Q3 | – | Sell |
-106,172
| Closed | -$744K | – | 1569 |
|
|
2022
Q2 | $744K | Buy |
106,172
+69,931
| +193% | +$513K | 0.11% | 272 |
|
|
2022
Q1 | $300K | Buy |
36,241
+12,313
| +51% | +$87K | 0.04% | 890 |
|
|
2021
Q4 | $162K | Buy |
+23,928
| New | +$157K | 0.02% | 1258 |
|
|
2021
Q3 | – | Sell |
-23,855
| Closed | -$137K | – | 1488 |
|
|
2021
Q2 | $137K | Sell |
23,855
-67,035
| -74% | -$346K | 0.02% | 1225 |
|
|
2021
Q1 | $419K | Sell |
90,890
-9,715
| -10% | -$38.6K | 0.07% | 445 |
|
|
2020
Q4 | $336K | Buy |
+100,605
| New | +$338K | 0.06% | 676 |
|
|
2020
Q2 | – | Sell |
-85,680
| Closed | -$330K | – | 693 |
|
|
2020
Q1 | $330K | Sell |
85,680
-101,816
| -54% | -$418K | 0.08% | 424 |
|
|
2019
Q4 | $703K | Buy |
187,496
+152,858
| +441% | +$715K | 0.08% | 422 |
|
|
2019
Q3 | $184K | Buy |
34,638
+8,418
| +32% | +$44.8K | 0.02% | 1189 |
|
|
2019
Q2 | $101K | Buy |
+26,220
| New | +$113K | 0.01% | 1344 |
|
|
2018
Q4 | – | Sell |
-202,845
| Closed | -$767K | – | 1398 |
|
|
2018
Q3 | $767K | Sell |
202,845
-177,760
| -47% | -$557K | 0.04% | 841 |
|
|
2018
Q2 | $1.19M | Buy |
380,605
+284,409
| +296% | +$863K | 0.06% | 637 |
|
|
2018
Q1 | $230K | Buy |
+96,196
| New | +$320K | 0.01% | 1422 |
|
|
2017
Q4 | – | Sell |
-479,196
| Closed | -$1.21M | – | 1590 |
|
|
2017
Q3 | $1.21M | Buy |
+479,196
| New | +$1.31M | 0.08% | 396 |
|
|
2016
Q4 | – | Sell |
-745,077
| Closed | -$812K | – | 1783 |
|
|
2016
Q3 | $812K | Buy |
745,077
+125,300
| +20% | +$113K | 0.04% | 737 |
|
|
2016
Q2 | $440K | Buy |
+619,777
| New | +$499K | 0.02% | 1151 |
|
Other funds holding CPRX
GCL
HI
GSA Capital Partners's CPRX Position: Q2 2026 in Review
GSA Capital Partners reduced its Catalyst Pharmaceutical (CPRX) stake by 46% in Q2 2026, selling an estimated $344K and leaving 13,574 shares worth $427K. The position accounts for 0.03% of the portfolio, ranked #1104.
GSA Capital Partners first reported a position in CPRX in Q2 2016 and has held it in 24 quarters since. The position peaked at $1.31M in Q4 2024. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- GSA Capital Partners held 13,574 shares of Catalyst Pharmaceutical worth $427K as of Q2 2026.
- GSA Capital Partners sold 11,640 Catalyst Pharmaceutical shares in Q2 2026, an estimated $344K.
- Catalyst Pharmaceutical made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1104 holding.
- GSA Capital Partners first reported a position in Catalyst Pharmaceutical in Q2 2016 and has held it in 24 quarters since.
- GSA Capital Partners's Catalyst Pharmaceutical position peaked at $1.31M in Q4 2024.
- 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.